Hội nghị công bố kết quả kinh doanh quý 3 năm 2026 của Enovis (ENOV): Nâng định hướng lợi nhuận và tăng trưởng tự thân 5%

Enovis (NYSE: ENOV) công bố doanh thu quý 3 năm 2026 đạt 559 triệu USD, với mức tăng trưởng hữu cơ đạt 5%. EPS điều chỉnh tăng 17% lên 0,88 USD, trong khi biên lợi nhuận và khả năng tạo tiền được cải thiện đã hỗ trợ nâng dự báo lợi nhuận cả năm cùng một chương trình mua lại cổ phiếu mới trị giá 200 triệu USD.

Những điểm nổi bật chính

• Doanh thu quý 3 tăng 2% so với cùng kỳ năm trước theo số liệu báo cáo và tăng 5% theo tăng trưởng hữu cơ. Việc thoái vốn khỏi Dr. Comfort đã làm giảm 250 điểm cơ bản mức tăng trưởng theo báo cáo, trong khi biến động tỷ giá hối đoái tạo ra lực cản 30 điểm cơ bản.
• Mảng Recon đạt tăng trưởng hữu cơ 6%, bao gồm mức tăng 8% ở mảng Chi và 5% ở mảng Khớp háng và Đầu gối. Mảng P&R tăng trưởng hữu cơ 3%.
• Biên EBITDA điều chỉnh mở rộng 120 điểm cơ bản lên 18,5%, trong khi EPS điều chỉnh tăng 17% lên 0,88 USD.
• Dòng tiền tự do đạt 35 triệu USD trong quý và 37 triệu USD lũy kế từ đầu năm, cải thiện 50 triệu USD so với cùng kỳ năm trước. Enovis duy trì mục tiêu năm 2026 về tỷ lệ chuyển đổi dòng tiền tự do đạt hơn 25%.
• Ban lãnh đạo đã thu hẹp phạm vi dự báo doanh thu cả năm xuống 2,32 tỷ - 2,35 tỷ USD, đồng thời nâng dự báo EBITDA điều chỉnh lên 428 triệu - 438 triệu USD và dự báo EPS điều chỉnh lên 3,58 - 3,79 USD.
• Enovis kỳ vọng thương vụ mua lại eCential Robotics sẽ hoàn tất vào cuối năm. Ban lãnh đạo tiếp tục đặt mục tiêu ra mắt robot phẫu thuật đầu gối trong vòng hai năm, và ứng dụng cho khớp vai dự kiến sẽ theo sau ngay sau đó.

Dữ liệu tài chính cốt lõi

Biên lợi nhuận gộp được hưởng lợi từ cơ cấu kinh doanh, năng suất hoạt động và 8 triệu USD tiền hoàn thuế quan. Những mức tăng này bị bù trừ một phần bởi khoảng 3 triệu USD áp lực lạm phát từ nguyên vật liệu cùng chi phí vận chuyển và phân phối liên quan đến cuộc xung đột ở Trung Đông.

Hiệu quả kinh doanh và hoạt động

Recon

Mảng Recon tại Mỹ tăng trưởng hữu cơ 5%. Mảng Chi tại Mỹ tăng 5%, trong khi mảng Khớp háng và Đầu gối tại Mỹ tăng 3%.

Nebula tiếp tục là động lực tăng trưởng chính của mảng khớp háng, với hơn 80% bộ dụng cụ mới được cung cấp cho các khách hàng đang sử dụng sản phẩm của đối thủ cạnh tranh trong quý. Ban lãnh đạo cho biết Nebula hiện là chuôi khớp háng bán chạy nhất của Enovis và vẫn đang ở giai đoạn đầu của chu kỳ sản phẩm kéo dài nhiều năm. Công ty tiếp tục cạnh tranh ở cả bệnh viện và các trung tâm phẫu thuật ngoại trú.

Tại Mỹ, đối với phẫu thuật đầu gối, hơn 25% một chút số ca phẫu thuật ban đầu được thực hiện tại các trung tâm phẫu thuật ngoại trú. Tỷ lệ này đạt khoảng 20% hoặc cao hơn một chút đối với khớp háng và ở mức cận 20% đối với khớp vai.

Tăng trưởng mảng khớp vai được hưởng lợi từ ARG và sự mở rộng liên tục của Arvis. Enovis đã hoàn thành các ca phẫu thuật khớp vai bằng hệ thống Arvis đầu tiên tại châu Âu trong tháng 10. Ban lãnh đạo đánh giá khớp vai là một thị trường lành mạnh và cho biết công ty tiếp tục giành thêm thị phần bất chấp môi trường cạnh tranh ngày càng gay gắt.

Mảng Recon quốc tế tăng trưởng hữu cơ 8%, dẫn đầu là mức tăng trưởng hai chữ số của mảng khớp vai. Điều kiện thị trường Tây Âu vẫn còn nhiều thách thức, trong khi cuộc xung đột ở Trung Đông đã làm giảm 100 điểm cơ bản mức tăng trưởng quốc tế và khoảng 40 điểm cơ bản tổng mức tăng trưởng của Enovis.

Prevention & Recovery

Tăng trưởng hữu cơ của mảng P&R đạt 3%, bao gồm 5% tại Mỹ. Mảng Nẹp chỉnh hình toàn cầu tăng 3%, nhờ cơ cấu sản phẩm và các sản phẩm mới trong phân khúc cột sống, đầu gối cốt lõi và nẹp chi dưới.

Mảng Recovery Sciences được hưởng lợi từ mức tăng trưởng hai chữ số của Regen khi Enovis đẩy nhanh quá trình ra mắt Manafuse và hoàn tất việc chuyển đổi khách hàng từ đối thủ cạnh tranh. Ban lãnh đạo cũng viện dẫn nhu cầu liệu pháp nhiệt lạnh liên quan đến Đạo luật NOPAIN và sự phát triển của danh mục sản phẩm thoái hóa khớp là những động lực tăng trưởng tại Mỹ.

Mảng P&R quốc tế vẫn chịu nhiều áp lực, đặc biệt là ở Pháp và Đức. Dẫu vậy, ban lãnh đạo cho biết hơn một nửa danh mục sản phẩm P&R đang tăng trưởng ở mức trung bình một chữ số hoặc nhanh hơn.

eCential Robotics và phân bổ vốn

Enovis đã hoàn tất quá trình tham vấn Hội đồng Doanh nghiệp đối với thương vụ mua lại eCential Robotics dự kiến và kỳ vọng giao dịch sẽ hoàn tất vào cuối năm. Kế hoạch tích hợp đang được triển khai, bao gồm việc hợp tác trong các chương trình phẫu thuật đầu gối và vai cũng như đầu tư vào nhân tài phát triển và công nghệ.

Ban lãnh đạo dự kiến giao dịch này sẽ làm tăng tỷ lệ đòn bẩy ròng thêm khoảng 0,5 lần. Công ty dự định duy trì tỷ lệ đòn bẩy trong khoảng 2,5x - 3,5x, đồng thời tiếp tục ưu tiên giảm nợ.

Hội đồng quản trị đã phê duyệt một chương trình mua lại cổ phiếu mới trị giá 200 triệu USD. Ban lãnh đạo cho biết việc mua lại sẽ mang tính cơ hội và có kỷ luật, chứ không phải là sự đi chệch khỏi các cam kết về đòn bẩy tài chính của công ty.

Dự báo của ban lãnh đạo

Ban lãnh đạo kỳ vọng mức tăng tốc khiêm tốn trong quý 4 ở cả hai phân khúc, được hỗ trợ bởi Arvis ở mảng Khớp vai, sự chuyển đổi khách hàng liên tục của Nebula và các sản phẩm P&R mới. Việc có thêm một ngày bán hàng dự kiến sẽ đóng góp khoảng 150 điểm cơ bản, hoặc cao hơn một chút, vào tăng trưởng doanh thu quý 4.

Triển vọng này giả định rằng bối cảnh thực hiện thủ thuật y tế trong quý 3 sẽ tiếp diễn cho đến cuối năm cùng với yếu tố mùa vụ điển hình của quý 4. Dự báo cũng bao gồm khoản đầu tư tăng thêm 4 triệu USD vào nhân tài R&D công nghệ hỗ trợ và tác động tiêu cực 1 triệu USD do biến động tỷ giá trong quý 4.

Đối với năm 2027, ban lãnh đạo tái khẳng định kỳ vọng đã nêu trước đó về tỷ lệ chuyển đổi dòng tiền tự do ít nhất 50% và tạo ra ít nhất 100 triệu USD tiền mặt. Công ty dự kiến sẽ cung cấp triển vọng đầy đủ hơn cho năm 2027 cùng với kết quả kinh doanh quý 4 và cả năm vào tháng 2.

Rủi ro và các yếu tố cần theo dõi

• Ban lãnh đạo mô tả thị trường thủ thuật y tế tại Mỹ và quốc tế là đầy biến động và “gập ghềnh”, viện dẫn các thay đổi về lịch trình, tình trạng hủy lịch và những cân nhắc về khả năng chi trả của bệnh nhân.
• Tình trạng suy yếu ở Tây Âu và cuộc xung đột tại Trung Đông tiếp tục gây áp lực lên tăng trưởng quốc tế và chi phí hậu cần.
• Kết quả kinh doanh mảng Bàn chân và Cổ chân yếu hơn dự kiến trong quý, dù ban lãnh đạo ghi nhận sự phục hồi vào đầu quý 4.
• Nếu không tính các khoản hoàn thuế quan, biên lợi nhuận gộp phải đối mặt với áp lực từ cơ cấu kinh doanh và chi phí lạm phát.
• Giao dịch eCential vẫn chưa hoàn tất tại thời điểm diễn ra cuộc họp công bố thông tin, và các kế hoạch thương mại hóa chi tiết cho nền tảng robot của công ty này vẫn chưa được hoàn thiện.
• Ban lãnh đạo dự kiến tỷ lệ đòn bẩy ròng sẽ tăng sau thương vụ mua lại eCential, làm hạn chế sự linh hoạt trong phân bổ vốn trong phạm vi đòn bẩy đã công bố.

Điểm nhấn phiên hỏi đáp với chuyên gia phân tích

Tăng trưởng mảng khớp háng và đầu gối tại Mỹ: Ban lãnh đạo thừa nhận biến động của thị trường nhưng cho biết Enovis tiếp tục đạt kết quả khả quan hơn so với thị trường chung. Công ty kỳ vọng Nebula, việc mở rộng danh mục sản phẩm và công nghệ hỗ trợ sẽ giúp gia tăng thêm thị phần, dù từ chối đưa ra dự báo chi tiết theo từng bộ phận giải phẫu.

Cạnh tranh ở mảng khớp vai: Enovis cho biết công ty vẫn là doanh nghiệp lớn thứ ba toàn cầu và lớn thứ hai trên thị trường quốc tế ở phân khúc khớp vai. Ban lãnh đạo kỳ vọng danh mục kết hợp giữa Lima và Enovis truyền thống, cùng với ARG và Arvis, sẽ hỗ trợ việc tiếp tục gia tăng thị phần trước đợt ra mắt robot phẫu thuật khớp vai theo kế hoạch.

Dòng tiền tự do: Ban lãnh đạo duy trì quan điểm rằng tỷ lệ chuyển đổi dòng tiền tự do có thể tăng lên ít nhất 50% vào năm 2027, với khả năng tạo ra ít nhất 100 triệu USD tiền mặt. Chi tiêu vốn dự kiến sẽ giảm tính theo tỷ lệ phần trăm trên doanh thu trong vài năm tới, mặc dù mức chi tiêu tuyệt đối sẽ tiếp tục tăng cùng với các khoản đầu tư vào mảng Recon.

Tích hợp Lima: Enovis cho biết năm 2026 sẽ là năm lớn cuối cùng cần đầu tư cho việc tích hợp Lima. Hiệu quả cộng hưởng đang đóng góp vào việc cải thiện biên lợi nhuận gộp, trong khi chi phí tuân thủ Quy định về Thiết bị Y tế của EU thấp hơn mang lại thêm lợi ích so với cùng kỳ năm trước.

Phản hồi của khách hàng về eCential: Ban lãnh đạo ghi nhận phản hồi tích cực ban đầu từ các bác sĩ phẫu thuật và đại diện bán hàng, đặc biệt là xoay quanh một hệ sinh thái kết hợp lập kế hoạch, định vị và hỗ trợ bằng robot tại cả bệnh viện và các trung tâm phẫu thuật ngoại trú.

Toàn văn biên bản cuộc họp công bố kết quả kinh doanh

Toàn văn cuộc gọi công bố kết quả kinh doanh

Phần trình bày của ban lãnh đạo

Operator

Good morning, and welcome to the Enovis Third Quarter 2026 Earnings Conference Call. [Operator Instructions] Please note this event is being recorded. I would now like to turn the conference over to Kyle Rose Rose, VP of Investor Relations. Please go ahead.

Kyle Rose

Good morning, everyone, and thank you for joining us today for our third quarter 2026 earnings conference call. I'm Kyle Rose, Vice President of Investor Relations. Joining me on the call this morning are Damien McDonald, Chief Executive Officer; and Ben Berry, our Chief Financial Officer.

Our earnings release was issued earlier this morning and is available in the Investors section of our website, enovis.com. We also posted a slide presentation to accompany today's call on our website. Both the audio and the slide presentation of this call will be archived on our website later today.

During this call, we'll be making some forward-looking statements about our beliefs and estimates regarding future events and results, including statements related to our pending acquisition of eCential Robotics. These forward-looking statements are subject to risks and uncertainties, including those set forth in the safe harbor language in today's earnings release and in our filings with the SEC. Actual results might differ materially from any forward-looking statements that we make today.

The forward-looking statements speak only as of today, and we do not assume any obligation or intend to update them, except as required by law. For further details regarding any non-GAAP financial measures referenced during this call, the accompanying reconciliation information can be found in our earnings press release and in the appendix of today's slide presentation.

With that, let me turn it over to Damien.

Damien McDonald

Thanks, Kyle. Good morning, everyone, and thank you for joining us today. I'll start with an overview of our third quarter results across Recon and P&R and give a short update on eCential Robotics. Ben will then walk through the financials and our outlook for the fourth quarter and the full year before we open the call for questions.

In the third quarter, we delivered organic growth of 5% with 6% organic growth in Recon and 3% in P&R. In U.S. Recon, we grew 5% organically with Extremities up 5% and Hips and Knees up 3%. In Extremities, we're now past the anniversary of the ARG launch, and ARG continues to be a strong growth opportunity for the future. As planned, Arvis is expanding in Shoulder, and we build upon the launch that began in Q2. Shoulder remains a healthy market, and it's where we have one of our leading share positions globally.

In Hips and Knees, Nebula continues to drive growth with over 80% of new instrumentation sets going to competitive users in the quarter. While we've now annualized the launch of the Nebula in the U.S., we remain in the early stages of a multiyear product cycle. I'm proud to note that it is now our top-selling stem, and we've got a long runway ahead of us. We're competing and winning in both hospital and ASC settings, and the ASC continues to be a good fit for our portfolio.

Internationally, Recon grew 8% organically. As we've noted the past several quarters, market dynamics in Western Europe remain challenging, and the conflict in the Middle East continues to weigh on growth. Despite these challenges, Shoulder grew double digits and led the international business. We continue to win competitive accounts outside the U.S., and I'm excited to announce we completed the first Arvis shoulder cases in Europe last month.

On eCential Robotics, we announced our binding offer to acquire the company on September 1. Since then, we have completed the Works Council consultation, and we expect the deal to close by the end of the year. Integration planning is well underway. Our Recon team is working with the eCential team in Grenoble on the knee and shoulder programs, and the time lines we laid out are unchanged. In fact, through our integration planning, we are making investments to secure the talent and technology required to accelerate our development upon deal close.

We expect to bring the knee robot to market within 2 years and shoulder to follow soon thereafter. Since the announcement, I've spent a lot of time discussing robots with surgeons. What I hear most is how much opportunity there is to develop innovative enabling technology and implant systems, which solve known problems and anticipate the evolution of surgical workflows and patient outcomes. This is an exciting inflection point for our Recon business, and we believe it will be a meaningful contributor to our sustained above-market growth.

Now moving to P&R, which grew 3% organically, including 5% organic growth in the U.S. Global Bracing grew 3%, driven by business mix and new products in spine, core knees and lower extremity bracing segments. Recovery Sciences was driven by double-digit growth in Regen as we accelerate the launch of Manafuse and capitalize on key competitive conversions.

Now I'll turn it over to Ben, who will walk through the financial details.

Phillip Berry

Thanks, Damien, and hello, everyone. We reported third quarter sales of $559 million, up 2% versus prior year on a reported basis and up 5% on an organic basis. Reported growth included a 30 basis point headwind from foreign currency and a 250 basis point headwind related to the divestiture of Dr. Comfort. As a reminder, Q3 is the last quarter in which the Dr. Comfort divestiture affects our year-over-year comparison.

Recon grew 6% organically with Extremities up 8% and up 5% in Hip and Knees. P&R grew 3% organically. The ongoing conflict in the Middle East was a 100 basis point headwind to international growth, which represents about 40 basis points to total Enovis growth in the quarter. We delivered adjusted gross margins of 60.9%, up 60 basis points, driven by mix and operational productivity. This includes $8 million of tariff refunds, offset by roughly $3 million of inflationary pressure from higher raw material and freight and distribution costs tied to the Middle East conflict. Our teams continue to work on mitigation actions to soften the overall impact of inflation in this dynamic market.

Adjusted EBITDA margin was 18.5%, up 120 basis points year-over-year. Our third quarter effective tax rate was 23%. Interest expense was $8 million for the quarter versus $9 million in the prior year. Overall, we posted adjusted earnings per share of $0.88, up 17% versus prior year. Free cash flow in the quarter was $35 million, bringing year-to-date free cash flow to $37 million, up $50 million versus the prior year. We remain confident in our 2026 target of greater than 25% free cash flow conversion.

I'm encouraged by the strong demonstrated progress we have made on cash generation, which now gives us more flexibility as we think about capital allocation in the future. We exited the quarter with net leverage of 2.9x, which is below the goal we set for the year. When the eCential transaction closes, leverage will step up about 0.5 turn.

While we remain committed to improving our balance sheet and paying down debt, we're also focused on continuing to make capital allocation decisions that we believe will drive long-term growth and shareholder value. To this end, today, we announced that our Board has authorized a new $200 million share repurchase program. We do not plan to materially waiver from our leverage commitments. However, we plan to use this opportunistically and stay within a range of 2.5 to 3.5x leverage. We see real value in our long-term growth strategy, and share repurchases are another tool we can utilize to create shareholder value.

Turning to full year guidance. We are narrowing our revenue range to $2.32 billion to $2.35 billion. We expect organic growth to be approximately 5%, and we are increasing our adjusted EBITDA range to $428 million to $438 million. We are also raising our adjusted earnings per share range to $3.58 to $3.79.

As we outlined last quarter, in Q4, we expect modest acceleration in both segments, driven by Arvis in Shoulder, continued Nebula conversions and new products in P&R. Our outlook assumes the procedural environment we saw in the third quarter holds through year-end with typical Q4 seasonality. On the profit side, our updated guidance assumes an incremental $4 million investment in enabling technology R&D talent and a $1 million negative impact from currency. We continue to expect free cash flow conversion of greater than 25% in 2026.

To summarize, the third quarter was in line with expectations we set in August in a market that remains dynamic. Cash generation continues to improve, and we are carrying new product momentum in both segments into the fourth quarter.

Now I'd like to turn it over to Kyle to start the Q&A. Kyle?

Kyle Rose

Thanks, Ben. [Operator Instructions]

With that, we would now like to open up the call to take your questions. Operator?

Operator

[Operator Instructions]

Our first question comes from Ryan Zimmerman of U.S. Bancorp BTIG.

Phần hỏi đáp

Iseult McMahon

This is Izzy on for Ryan. I just wanted to start on the U.S. Recon business, specifically with Knees and Hips. It was a little bit softer than what we saw your growth for both Extremities and the international business. And we've heard some comments from your peers about softness in the large joint market. So I was curious what your take is on the outlook of the market and what will help get your knee and hip growth back in line or better with that.

Damien McDonald

Thanks for the question. Look, we've been saying since Q1 that the market is more volatile than we've normally seen both in the U.S. and internationally. I know there's a lot of soil about markets, even from those who have much larger perspectives than we do. But we're focused on controlling the controllables. It's a dynamic market environment. We think we're building a strong, resilient customer organization. So our focus is really on gaining market share and candidly, not being a victim to the market.

Iseult McMahon

Understood. That's helpful. And I understand that it's still a little bit on the early side, but I was hoping you could maybe provide some color on your thoughts around 2027.

Damien McDonald

Yes. With 2027, we're going to point everyone back to what we outlined in September when we did the eCential announcement. Our view hasn't changed since then, and we're going to comment fully in February when we do the Q4 full year results.

Operator

Our next question comes from Vijay Kumar of Evercore ISI.

Vijay Kumar

I guess my first one, when you look at this Recon assumptions getting back to high singles in Q4, is the bridge between [ CQ ] to Q4 just the comp from the headwinds? Could you also comment on what's happening within ASCs? What percentage of Recon procedures are being done in ASCs and what's the growth rate in been?

Phillip Berry

Vijay, thanks for the question. Yes, I think as you recall, we had an extra selling day in Q4. So that's going to contribute about 150 basis points, a little bit more than that to the top line growth. So that plus some of the dynamics that we talked about with just normal Q4 seasonality will drive some of the acceleration there.

In terms of ASC, we continue to see movement there. In terms of our knee business, I think what we're seeing is a little over 25% of primary knees going through the ASC. It's about 20% or a little bit more than that in hips, and we're climbing closer to that hip number and shoulder. We're still in, I'd say, the high teens in terms of percentage of our procedures going through the ASC. So we see the ASC as a continued strategic channel for us and one that we will continue to be focused on in terms of setting our business up for success.

Vijay Kumar

That's helpful. Then maybe one on free cash. Third quarter was pretty impressive, 68% free cash conversion. Is this a sustainable number for you guys when you think about fiscal '27? I know with the deal coming on, like the impact of free cash conversion or is a sustainable number?

Phillip Berry

Yes. Thanks, Vijay. Again, we'll point you back to what we talked about in September, where we see a step-up to at least 50% free cash flow conversion next year and $100 million of cash generation. So we still see line of sight to that. We'll try to do better than that. But overall, I'll point you back to that in terms of thinking about next year.

Operator

The next question comes from Jeff Johnson of Baird.

Jeffrey Johnson

Damien, maybe a follow-up on your comment about controlling the controllable. U.S. hip and knee growth was 3% this quarter. It does seem, as others have said that the U.S. market, especially for U.S. hips and knees, may have slowed a bit this quarter. Just are you seeing anything even if you can or can't control, I guess, surgical schedules, higher cancellation rates, extended willingness to pay co-pays, deductibles, things like that, so patients slowing down. Anything at all there?

And then I guess the corollary or follow-up on that is just that you talked about Nebula being one of the drivers of acceleration in 4Q. So if U.S. hip and knee was 3% this quarter, you pick up the extra day, that's 4.5% and then Nebula on top of that, should we see U.S. hip and knee growth above the mid-single digits next quarter?

Damien McDonald

So was there an option D there that was like all of the above? That's -- I'd point you to that. I think all of the things you mentioned, we're seeing all of that. It's pretty choppy. And we're, as I said, very focused on market share gain and using EGX to get after the targeting and segmenting account acquisition, account penetration, being very disciplined on price and, again, making sure we have the best sales force. So we're doing a lot on sales force training. So the way we're countering all of those things that you mentioned is by focusing on our performance.

Phillip Berry

Yes. In terms of hip and knee growth in the U.S., Jeff, we don't guide particularly on anatomy level growth given some of the dynamics in the market that Damien talked about. But we see momentum building there. We still see a large opportunity in U.S. hips and knees in terms of ability to take market share as we continue to reinforce the portfolio and build more strength there with enabling tech. So overall, I think the way you're thinking about it makes sense. But like I said, we don't guide for anatomy level.

Jeffrey Johnson

Yes, fair enough. And then just one follow-up. I think last quarter, that low single-digit U.S. shoulder number is what caught a lot of us off guard. I think you explained it well with some of your Arvis shoulder training during the period last quarter. So that all made sense, encouraging to see that shoulder number get back to high single digits in the U.S. this quarter. But just what can you talk about the competitive environment?

You do have a couple of your competitors out there with new shoulder systems, maybe even some robotic applications in shoulders, even though early stage there. Just how to think about the shoulder competitive environment and until you get the robotic option out in a couple of years on shoulder, can you sustain market, above-market growth? How are you thinking about that in the U.S.?

Phillip Berry

Yes. I mean I think it's definitely a competitive environment. We're pleased with our position in the market. We believe we're continuing to take share. We're the global #3 player in shoulder, #2 internationally, knocking on the door of being #2 globally. We really are encouraged by the portfolio that we've built in the shoulder in terms of the dynamics that we have in terms of products that can be used for different philosophies.

That continues to build with new product innovations, things like ARG that are complementing that overall portfolio. Putting the Lima and legacy Enovis portfolios together just adds strength, adds compatibility, gives more options. And what we're really seeing right now is really strong uptake and interest in the Arvis platform. And given where shoulders are in terms of the enabling tech curve, which still needs a lot of development in terms of use cases there, we feel like Arvis will continue to be a player here in terms of giving the surgeons enabling tech tools that really help aid them in a way that makes surgery more efficient in the shoulder.

So we're encouraged by the portfolio, the momentum, Arvis' contribution to that, and we would expect that to continue into the future.

Operator

Our next question comes from Robbie Marcus of JPMorgan.

Unknown Analyst

This is Lily on for Robbie. One on guidance, you beat EPS by about $0.11, but guidance by my math is moving up by [ $0.05 ] at the midpoint. So hoping you can unpack that a bit more. Why not flow through the full upside? And are there any incremental headwinds or expenses down the P&L we should be baking into the fourth quarter?

Phillip Berry

Lily, thanks for the question. As I mentioned in our prepared remarks, we're investing in enabling tech resources, particularly in R&D to really get ahead of bringing eCential into the family. We see lots of opportunities to really derisk that program and to add some strength with regards to talent within the organization. So that's about $4 million that we're going to make investments in Q4 to support that acquisition. On top of that, currency has moved in a negative way since last quarter. So that's going to hit us for about $1 million in Q4. So contemplating those 2 things is really the reason why we didn't flow everything through.

Unknown Analyst

Great. And then just a follow-up to that. You delivered pretty significant SG&A leverage this quarter with expense actually down a bit year-over-year. So what drove that? And was there anything onetime or timing that drove the greater-than-expected leverage in the third quarter?

Phillip Berry

Yes. Nothing I would point to as onetime. Overall, I think it's just phasing of expenses through the year. We generally invest a little bit heavier in the first part of the year. You have the softer Q3 with regards to international markets, and that generally reduces expenses in the quarter. So overall, nothing unexpected there, and it's just really phasing.

Operator

Our next question comes from Lawrence Biegelsen of Wells Fargo.

Ross Osborn

This is Ross Osborn for Larry. Starting off, I would be curious to hear where Lima stands. How much integration spending carries into '27? And how much of the 50 bps underlying EBITDA margin expansion comes from Lima synergies versus improvement elsewhere in the business?

Damien McDonald

The integration expense in the quarter?

Phillip Berry

So Lima integration expense? So yes, I think we continue to -- like we've laid out, this is the third year of integration on the Lima, where we're continuing to finish a lot of that journey with regards to the investments we needed to make to integrate that into the organization. So we're continuing to track to our stated plans there. This will be the last big meaningful year of investments in integration on Lima, and it's going very well in terms of the way that we laid out the plan in terms of executing against that plan. And a lot of what we're doing this year is cleaning up some things, moving some things from manufacturing to other locations. So that's all continuing to track.

In terms of the synergy value, yes, it continues to contribute to our mix and gross margins. We see that as an opportunity to continue to drive improvement there. And that is one of the key drivers as we lay out how do we drive our 50 basis points of improvement every year. So it's a contributor. It's not the contributor. But overall, I'd say it's tracking to what our expectations were.

Damien McDonald

I mean the other one that's stepping down a lot too is the EU MDR, right? So year-over-year, that's the other step down.

Ross Osborn

Okay. Great. And then on capital deployment and with your leverage within your comfort range and a new $200 million authorization program, is repurchasing shares now a near-term priority or more so optionality? And what capacity remains after eCential? And how do you rank buyback against that reduction in M&A?

Phillip Berry

Yes. Thanks, Ross. I mean we believe that the company's valuation is significantly below where our value lies. You look at where the stock has traded off quite considerably over the last 12 months. And it's dislocated given our performance and our outlook for the future. So what we wanted was flexibility to take advantage of this dislocation. And as we think about share buybacks, we're going to be very much opportunistic, disciplined and focused on how we do that. And it's really going to depend on if we feel like the shares are really dislocated from where they should be. And right now, the way the value that we're trading, we would say that we do see that. So we will use this as a capital allocation tool. But like I said, we'll be disciplined about how we deploy it.

Operator

Our next question comes from Young Li from Jefferies.

Young Li

I guess to start, just on eCential. So this deal hasn't closed yet, but what has been the early feedback on that from your customer base as well as from your reps? Are there any features that eCential offers that the customers or reps are more excited about?

Damien McDonald

I have to say we've had a great response from our customers, both on the knee side and the shoulder side. In fact, Ben and I just last night were with a group of physicians that we're very close to, and we had a long conversation about this. In both therapeutic areas, both anatomies, there's a lot of excitement about what we can bring to the table. And it's not just about the robot. It's -- we've always talked about enabling tech planning, navigation assistance. And we think the whole ability to bring an ecosystem to an offering for physicians is really key here and meeting the physician where they are.

So a lot of people work in large hospitals and then they also work in small ASC clinics and being able to give them an ecosystem that seamlessly moves between those venues, we view as exciting and so do they. The reps are just excited to be able to compete. In terms of a contractual basis, a lot of accounts require the assistance part of the equation. We've got that now coming into the bag, and I think they view that as a really great opportunity to compete. And candidly, a lot of shareholders also viewed it as that just being able to compete head-to-head and also shape the direction of where we're going in shoulder with a new form factor is exciting.

Phillip Berry

Yes. And I'll pile in there, Young. I think that we continue to be very impressed with the eCential team, their talent, their ability to collaborate, the speed in which they operate. So overall, we're really excited about this acquisition and what it's going to bring to Enovis in the future.

Young Li

Okay. Great. Really helpful. And then just one more just on the U.S. extremities side, shoulders leading the growth there. Can you talk a little bit more about what's going on in the U.S. foot and ankle side? That market is typically viewed as a little bit more deferrable kind of like knees. How is that business doing? Any changes in the macro or competitive dynamics you call out?

Phillip Berry

Yes. Thanks, Young. I think foot and ankle market is -- continues to be a little bit volatile quarter-over-quarter. I think underlying performance through the first 9 months, we're very pleased with the foot and ankle business. Portfolio continues to get stronger with some of the new innovations that we're launching. We've got some other things coming here later this year and into next year that we're really excited about. We still see this as a market that over time is going to grow into the high single-digit range, and we're really excited about the portfolio that we're putting together to continue to capitalize on that growth and take share.

So overall, I'd say in the quarter itself, it was a little bit softer than what we would have anticipated. Could that have been some deferrals? Maybe. If we look at where it was coming from certain product lines, it's nothing that we're concerned about, and we saw a nice rebound as we stepped into the first month in the fourth quarter there. So overall, I think foot and ankle continues to be a growth driver for us, and we're excited about the portfolio we're building.

Quarter-over-quarter, there could be things that pop up. But overall, if you look at it over the course of time, we expect this business to continue to grow high single-digit plus.

Operator

The next question comes from Caitlin Roberts of Canaccord.

Unknown Analyst

This is Michaela on for Caitlin. Just one from us today. We were just wondering if -- are you seeing any impact from recent competitive dynamics, including the new knee launch from one competitor and then the weakness another has called out in hips related to the lack of an impact?

Damien McDonald

Again, I think we've got a great knee portfolio, and we're continuing to take share with that, which is exciting. On the impactor side, we can definitely tell you that having an impactor and by the way, a triple-tapered collared stem with Nebula has really made a tremendous impact on our ability to take share and partner with new clinics. So definitively, an impactor is a key part of that equation.

Operator

Our next question comes from Vik Chopra of BMO.

Vikramjeet Chopra

I had 2, and apologies if these have been asked, I've been bouncing around. So you said that U.S. hips and knees grew 3% in the quarter. By our math, that's still ahead of the market. I'm just curious what you're seeing in underlying procedural volumes exiting the third quarter? And how much of that growth represents share gain versus the market? And I had a quick follow-up.

Phillip Berry

Yes. I think, Vik, the way that we see it is, yes, we continue to feel positive with regards to our U.S. hip and knee performance if you stack it up versus the overall market. We have seen some nice start to Q4 here. Again, it's still early in the quarter. So we'll have to see how that plays out. But overall, as Damien mentioned, we're excited about the portfolio we're building there, still see a large opportunity for us in growth in terms of our hips and knees, particularly in the U.S. market.

Vikramjeet Chopra

Great. You delivered about 5% organic growth in the third quarter. As we look into 2027, maybe just talk at a high level about the biggest drivers and potential offsets to sustaining that 5% or better organic growth.

Damien McDonald

Again, without commenting on '27, I think what gives us confidence about going into the new year in a choppy market, and there's been a lot of talk about that in various forums, we've continued to take share in global hip and knee, global shoulder. P&R is growing above the market. So I think our underlying performance and commercial execution is what gives us confidence about how we not only finish off the year, but where we're heading into next year.

Operator

Our next question comes from Steve Lichtman of William Blair.

Steven Lichtman

I wanted to ask on the P&R business. It's delivered a pretty steady 3% underlying growth here over the last few quarters. Can you give us your latest outlook on the market there and the state of your business overall? Just sort of how you're feeling overall about where your P&R business sits today?

Damien McDonald

Yes. We're really proud of how that business has shaped. We've talked about the portfolio now that more than 50% of it is growing mid-single digit or greater. I think the team is really executing in the U.S. really, as in my prepared remarks, Regen with Manafuse has done a great job of doing competitive conversions, and that's really leading the way. But broadly, we've got some great things going on and some tailwinds like the NOPAIN Act driving cold therapy and where we're going with the OA portfolio.

So I think in the U.S., we're seeing really solid above-market performance there. Internationally has been challenged. I mean we have a big presence in international. And we've talked about markets like France and Germany where -- by the way, we skew towards France and Germany for that portfolio being under pressure. But again, I think those teams are working hard to counter all of those changes and the dynamics in those markets. So overall, we're really, really pleased with how that group is going.

Steven Lichtman

Great. And then just a follow-up. Ben, you highlighted some of the drivers of free cash flow improvement. Sorry if I missed it, but one thing I'm not sure you mentioned was leverage on the CapEx side. It looks like that was down. Is that more of a timing thing? Or do you see that continuing to run lower year-over-year? And what might be driving that?

Phillip Berry

Yes. Thanks, Steve. I think if you look at how we deploy instruments in CapEx, it's generally first half weighted, so we can capitalize on those placements throughout the course of the year and as we build into next year. So I'd point it more towards the phasing of spend versus anything at this point. Overall, I'd say we see capital -- CapEx as a percentage of sales to tick down over the next couple of years, but it will continue to grow because of the investments that we're making on the Recon side of the business.

Operator

The next question comes from Mike Matson of Needham.

Joseph Conway

This is Joseph on for Mike. Maybe just a couple of product ones on P&R. It looks like maybe in the quarter, there was some SKU rationalization or discontinuing a product maybe in U.S. other P&R. So just wondering what that was and maybe the reasons for that? Is it a margin problem that was being addressed?

And then maybe just MotionMD, you guys called out penetration there in the slide deck. I saw on the website that you guys list some metrics there, including maybe 75 integration partners. I'm just wondering in terms of penetration, what's the ceiling there, if you can quantify it at all? And how is growth looks like in that product?

Phillip Berry

Yes. Thanks, Joseph. I think what you're referencing is the divestment of Dr. Comfort that we did last year. So this is the last quarter that that's in the comparable, but that is what's driving that down in terms of the rationalization, I believe.

Damien McDonald

And on MotionMD, we don't declare the metrics broadly. But I will say there's a number of things that are really important for us. We have a 99% customer satisfaction rating with the software and the service that's attached to that. And that provides enormous stickiness. Again, without declaring the the number of accounts that we service, it's a significant number and growing year-on-year. And we've got demonstrable ability to show how we can reduce inventory at the clinic level, how we increase the speed of processing of claims and the return of claims. So we're very, very proud of how that team works, and it's a real core competency and, I think, a differentiator in the P&R space.

Joseph Conway

Okay. Great. Yes. And then maybe just on the robotics launch. I guess my assumption for the launch in 2028 would be to target current customers that are already using ASTRA, Arvis and Portal. But maybe you can touch on that strategy, whether it's more broad-based or targeted. And just based on your initial conversations, you guys have a good idea, what's maybe your expectation of how many of those ASTRA customers would be interested in integrating robotics or maybe you feel comfortable with just the navigation and planning of Arvis and Portal?

Damien McDonald

Yes. That's a whole bunch of questions there, and we don't even own the company yet. So first, we're interested in getting to the close, which we think is on track to be done before year-end. Once we do that, we'll start talking about how we are going to frame this up, but I'm definitely not in a position to talk about strategy yet, but we certainly have some great ideas. And again, as I said earlier, the reaction to this from our key customers has been really very positive.

Phillip Berry

Yes. And I'll just weigh in there, too. I mean I think we see an ability here to create a seamless ecosystem between Arvis and the robot. And as we do that, we don't believe there's a one-size fits all. So we'll continue to try to leverage this to take as much market share as we can and to really drive penetration into the market as best we can. But I think it's still a little bit early in terms of our go-to-market approach. But overall, I think we're going to have some flexibility for customers and some really good products for them to leverage.

Operator

The next question comes from Nakul Desai of Freedom Capital Markets.

Nakul Desai

This is Nakul on for Keith. We have just one quick one. So if we exclude the tariff refund, gross margin was down approximately 80 basis points year-over-year. So can you give any color on what the drivers were there and how we should think about gross margin in 4Q and heading into 2027?

Phillip Berry

Yes. I think the way to really think about it, it's the mix of the business in the third quarter that was really driving that and some of the pressure points that we saw there. So overall, that's the key contributor. Not commenting on guidance in terms of that line for the fourth quarter. But overall, I think we still see gross margin as the company grows and as Recon becomes a bigger part of the portfolio, we see opportunities to expand gross margins year-over-year.

Operator

[Operator Instructions] This concludes our question-and-answer session. I would like to turn the conference back over to Damien McDonald, CEO, for any closing remarks.

Damien McDonald

Thanks, Cindy, and thanks, everyone, for joining us today. The third quarter played out largely as we expected, and I want to thank our teams for delivering on our commitment and to take share regardless of the challenges posed by the dynamic and volatile markets we face. We appreciate all of you for your continued interest. Thanks for your support, and we look forward to updating you in the fourth quarter and our full year results in February. Thanks, everyone.

Operator

The conference has now concluded. Thank you for attending today's presentation. You may now disconnect.